Larotrectinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Larotrectinib
Larotrectinib.svg
Identifiers
CAS Number
ChemSpider
UNII
Chemical and physical data
3D model (JSmol)

Larotrectinib (LOXO-101, ARRY-470) is an experimental drug for the treatment of cancer.[1] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.

Larotrectinib was awarded orphan drug status in 2015 for soft tissue sarcoma and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.[2]

Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.[3]

Some clinical trial results were announced in 2017.[4]

References[edit]

External links[edit]